Restasis®
Cyclosporine 0.05% · ophthalmic emulsion
Dry Eye/OSD
Approved uses
Keratoconjunctivitis sicca with tear production presumed suppressed by ocular inflammation
One drop in each eye BID, approximately 12 hours apart
Effect is read at 6 months, with no added benefit from the higher 0.1% strength.
OFF-LABELNot in the FDA label for this product
Meibomian gland dysfunction (posterior blepharitis)
One drop BID for 3 months, the regimen used in both randomized trials
2 RCTs · n=103 · signs only
Perry 2006, randomized versus preservative-free artificial tears, 33 enrolled and 26 completed: at 3 months lid margin vascular injection, tarsal telangiectasis, fluorescein staining, and meibomian gland inclusions (P = 0.001) improved against control, while the symptom difference was not statistically significant and the authors concluded topical cyclosporine may be helpful but did not improve symptoms. Prabhasawat 2012, randomized double-masked versus 0.5% carboxymethylcellulose, 70 patients: tear breakup times were longer at every visit and the change from baseline greater at 3 months (P < 0.001), with the authors attributing the benefit mainly to tear film stability. Both are small single-center trials showing signs moving more than symptoms.
Contraindications
Known or suspected hypersensitivity to any ingredient in the formulation.
0.05% (0.5 mg/mL) preservative-free emulsion, 0.4 mL single-use vials, 30 or 60 vials per tray that must be dispensed intact
Topical calcineurin inhibitor immunosuppressant. In patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca, it is thought to act as a partial immunomodulator, and the exact mechanism of action is not known. Six months of treatment raised conjunctival goblet cell numbers over baseline on biopsy and pooled trials put goblet cell density above control, though a Cochrane review says this has not been shown to translate into symptom or tear film benefit.
Warnings & Precautions
- Eye injury and contamination: Contact between the vial tip and the eye or any other surface risks eye injury and contamination of the emulsion.
- Use with contact lenses: Not to be administered during lens wear, and patients with decreased tear production typically should not wear contact lenses; remove lenses before instillation and reinsert 15 minutes afterward.
Common Side Effects
The most common adverse reaction was ocular burning (17%). Other reactions reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring). Post-marketing reports have included hypersensitivity (including eye swelling, urticaria, rare cases of severe angioedema, face swelling, tongue swelling, pharyngeal edema, and dyspnea) and superficial injury of the eye from the vial tip touching the eye during administration.
Pregnancy: Blood levels are undetectable after topical ocular dosing and fetal exposure is not expected. Oral cyclosporine was not teratogenic in rats or rabbits at clinically relevant doses; teratogenicity appeared only at maternally toxic doses about 5,000 (rat) and 32,000 (rabbit) times the daily recommended human ophthalmic dose.
Lactation: Cyclosporine appears in human milk after systemic administration; its presence after topical ocular dosing has not been investigated, and blood concentrations after topical dosing are below the limit of quantitation. Caution should be exercised when the drug is given to a nursing woman, weighing the benefits of breastfeeding with the mother's clinical need and any potential adverse effects on the breast-fed child.
Safety and efficacy not established below age 16.